Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Bio-Rad Laboratories (NYSE:BIO) Full Year 2024 Results

Key Financial Results

• Revenue: US$2.57b (down 3.9% from FY 2023).
• Net loss: US$1.84b (loss widened by 189% from FY 2023).
• US$65.37 loss per share (further deteriorated from US$21.82 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bio-Rad Laboratories EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.

The primary driver behind last 12 months revenue was the Clinical Diagnostics segment contributing a total revenue of US$1.54b (60% of total revenue). The most substantial expense, totaling US$2.11b were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how BIO's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 10% from a week ago.

Valuation

Our analysis of Bio-Rad Laboratories based on 6 different valuation metrics shows it might be undervalued. To explore our complete evaluation click here and get an understanding of what analysts are thinking about the company's future.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.